INTRODUCTION: In this study, our aim was to analyze Pap smear cervical cancer screening results at our hospital. We also sought to compare our ASC/SIL rate with the relevant studies in the literature, which is one of the quality standard criteria for the pathology laboratory.
METHODS: In our study, digital reports of 6902 cases diagnosed according to the Bethesda Reporting System for Pap cervical cancer screening and other medical indications in the pathology department of our hospital between 1st January 2018 and 31st December 2018 were reviewed retrospectively.
RESULTS: When 6902 cervicovaginal smear cases were analyzed concerning epithelial abnormality, 6528 cases (94.6%) were reported as NILM, and seven cases (0.1%) were reported as an inadequate smear. Epithelial abnormality was detected in the remaining 367 (5.3%) cases. Out of 367 cases,279 (4.0%) of them were reported as ASC-US;42 cases (0.6%) as AGC-NOS;24 cases (0.3%) as LSIL;12 cases (0.2%) as ASC-H, seven cases (0.1%) as HSIL; one case (0.0%) as LSIL and AGC-NOS; one case (0.0%) as ASC-H and AGC-NOS and one case (0.0%) as squamous cell carcinoma (SCC). The ASC/SIL rate of our laboratory for the year 2018 was 9.125.
DISCUSSION AND CONCLUSION: Our SCC rate was 0.02%, which was the second-lowest rate in the relevant literature. The reason for this may be the success of the cervicovaginal Pap smear screening program performed in our region. Our inadequate cervicovaginal smear rate concerning assessment was the lowest rate in the literature. Our ASC/SIL rate was 9.125, and this was the third highest ASC/SIL rate in the literature. The reason for our laboratorys 2018 ASC/SIL rate of 9.125 may be the concern of some of our pathologists of false-negative reports. We detected various differences between epithelial abnormality and infection prevalence in the cervicovaginal smears in our region and epithelial abnormality and infection prevalence in different regions of the world. Intra-departmental case presentations and in-service training could be organized to keep the ASC/SIL rate in the pathology laboratory under three. At the same time, pathologists quarterly ASC/SIL rates could be calculated and reported to the pathologists.